HomeAI · summaries
Storia in 4 fonti
People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
adnkronos.com
ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows
GLASGOW, Scotland, June 4, 2026 /PRNewswire/ -- New findings from the landmark FLOW trial, presented at the 63rd ERA Congress, show that once-weekly semaglutide significantly…
- ·
morningstar.com
People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to…
People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than…
- ·
medpagetoday.com
Up to 40% of Diabetes Patients Achieved Normal HbA1c With Retatrutide
But its key advantage is in its weight reduction abilities
- ·
healio.com
CagriSema confers ‘high magnitude’ of HbA1c, weight reductions in type 2 diabetes
NEW ORLEANS —A once-weekly combination therapy of cagrilintide and semaglutide reduced HbA1c and body weight across a wide range of adults with type 2 diabetes, according to data…